On Tuesday, 1422 stocks advanced, 2802 declined and 160 remained unchanged on Bombay Stock Exchange with advance decline ratio of 0.51 indicating a negative closing. The trend of the major indices on Tuesday’s trading is given in the table below.
On NSE, 55 securities advanced and closed at a new 52-week high whereas 303 securities sank to close at their new 52-week lows. Nifty Metal, Nifty Energy and Nifty PSU Bank among the biggest gainers. Nifty IT, Nifty Media and Nifty Infrastructure among the biggest losers
Adani Power’s (+0.18%) subsidiary Moxie Power Generation Ltd. (MPGL) has received a Letter of Award (LoA) from TNPDCL to supply 558 MW (net) of power for five years, starting at a tariff of ₹5.910/unit. With this, both units of MPGL’s 1,200 MW Tuticorin plant are now fully backed by PPAs, ensuring capacity utilization and operational stability. Following the award, over 95% of Adani Power’s 18.15 GW capacity is secured under medium to long term contracts, reducing merchant market exposure and enhancing revenue predictability.
Rail Vikas Nigam Limited (RVNL) (+0.77%) received a Letter of Acceptance (LOA) from Central Railway for a traction infrastructure project on the Daund–Solapur section, valued at ₹270.22 crore (incl. taxes). The scope covers design, supply, erection, testing and commissioning of a 220/132/55 KV traction substation, Sectioning Posts (SPs), and Sub Sectioning Posts (SSPs) under the 2×25 KV system with Scott Connected Transformers, executed on an EPC mode. The project, awarded by a domestic entity, carries a 24 month execution timeline.
IDFC FIRST Bank (+1.33%) informed exchanges that it has paid out ₹583 crore (principal + interest) to the Haryana Government departments on February 24, 2026, even as investigations into the fraud remain ongoing. The bank emphasized that the move reflects its customer first principles and commitment to professional, principle based resolution, choosing not to delay payment despite the probe. Government departments have acknowledged and appreciated the timely resolution.
Centum Electronics (+4.00%) received a ₹66 crore Phase 1 order (₹78 crore gross incl. GST) from HAL for the design and development of AESA Radar Systems for the Utility Helicopter–Maritime (UH M) platform. The radar will enable multi target maritime detection, classification, and tracking, enhancing surveillance and operational effectiveness. Upon successful completion, the programme will move to Phase 2 serial production, with an indicative value of ₹500 crore (₹590 crore gross incl. GST) over five years.
Alembic Pharmaceuticals (-2.40%) received final USFDA approval for its ANDA of Efinaconazole Topical Solution, 10%, a biosimilar to Jublia® marketed by Bausch Health. The product treats onychomycosis of toenails caused by Trichophyton rubrum and T. mentagrophytes, two common fungal pathogens. With an estimated $500 million US market size (IQVIA, Dec 2025) and Alembic’s Paragraph IV certification, the approval strengthens its US generics portfolio.
Himadri Speciality Chemical (-0.44%) commenced commercial operations of its expanded Speciality Carbon Black line with a capacity of 70,000 MTPA at its Mahistikry facility, Hooghly, West Bengal. This brownfield expansion lifts total Carbon Black capacity to 2,50,000 MTPA, of which 1,30,000 MTPA is dedicated to Speciality Carbon Black, making Mahistikry the largest single‑site Speciality Carbon Black facility globally.
KEC International (+1.38%) part of the RPG Group, has secured orders worth ₹1,002 crore across its Transmission & Distribution (T&D) and Cables & Conductors businesses. The wins include 220/132 kV transmission lines, substations, and EHV cabling in India, a 400 kV transmission line overseas, and supply contracts for towers, hardware, and poles in the Americas. Its Cables & Conductors division also bagged supply contracts in both domestic and international markets, reinforcing steady traction and strengthening KEC’s power infrastructure order book.
Eris Lifesciences (+2.36%) entered into a strategic partnership with Natco Pharma Limited to commercialise semaglutide in India, marking a significant push into the fast‑growing diabetes and metabolic care segment. Natco recently received approval to manufacture generic semaglutide, paving the way for a launch in March 2026. The collaboration combines Eris’ strong commercial presence in diabetology with Natco’s manufacturing and regulatory expertise, positioning both companies to capture rising demand for GLP‑1 therapies in India.
Balkrishna Industries (+0.38%) commissioned the first phase of its Bhuj facility expansion, adding 800 tyres per day capacity with an investment of ₹750 crore funded via internal accruals. This follows earlier approvals of ₹1,300 crore (Aug 2024) for Off‑Road Tyres and ₹3,500 crore (May 2025) for expanded facilities covering Carbon Black, Power Plant, CV Tyres, Rubber Tracks, and PCR Tyres.
Caplin Steriles received final USFDA approval for its ANDA of Sodium Phosphates Injection USP in multiple strengths — 15mM P/5mL, 45mM P/15mL, and 150mM P/50mL single dose vials. The product is a generic equivalent of Hospira’s RLD (NDA 018892) and is indicated as a source of phosphorus, primarily used to prevent or treat hypophosphatemia and in parenteral nutrition formulations.
Indoco Remedies (+1.65%) received final USFDA approval for its ANDA of Brivaracetam Oral Solution, 10 mg/mL, strengthening its regulated markets portfolio. The drug, an antiepileptic (AED), is indicated for the treatment of partial‑onset (focal) seizures in patients aged one month and older.
Shilpa Medicare (-1.90%) through its subsidiary Shilpa Biologicals Pvt. Ltd., has entered into a strategic licensing agreement with SteinCares to commercialize a biosimilar across Latin America. Under the deal, SteinCares will hold exclusive rights to register, distribute, and commercialize the product region‑wide, while Shilpa Biologicals will complete development and manage long‑term manufacturing from its Dharwad biologics facility. The partnership combines Shilpa’s biologics expertise and integrated manufacturing with SteinCares’ regulatory and market access network, enabling faster registration and broader reach of affordable biologic therapies in emerging markets.
The top gainers and top losers of the major indices are given in the table below:
The closing values of the major Asian indices are given in the table below:
